Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm

Yoshiaki Nakamura(National Cancer Center Hospital East), Kohei Shitara(National Cancer Center Hospital East), Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Florian Lordick(Leipzig University), Akihito Kawazoe(National Cancer Center Hospital East)
Nature Reviews Clinical Oncology
March 31, 2021
10.1038/s41571-021-00492-2
Cited by 301

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Gastric cancer
|The Lancet|2020|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k